Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,365 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00856375 | NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer | completed | Phase 2 | 83 | Nektar TherapeuticsINDUSTRY | 6 | Jul 12, 2021 | clinicaltrials |
| NCT01457118 | An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies | completed | Phase 2 | 27 | Nektar TherapeuticsINDUSTRY | 2 | Jul 12, 2021 | clinicaltrials |
| NCT01138722 |
| Predicting Cell Death by Radiation Therapy in Early Stage Non-small Cell Lung Cancer: a Prospective Translational Trial(PEARL-1) |
| terminated |
| Phase 2 |
| 1 |
| University Hospital, GhentOTHER |
| 1 |
| Jul 8, 2021 |
| clinicaltrials |
| NCT00109707 | A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies | completed | Phase 1 / Phase 2 | 507 | Novartis PharmaceuticalsINDUSTRY | 22 | Jun 29, 2021 | clinicaltrials |
| NCT01275222 | Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors | completed | Phase 1 / Phase 2 | 117 | Novartis PharmaceuticalsINDUSTRY | 4 | Jun 25, 2021 | clinicaltrials |
| NCT01719380 | Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer | completed | Phase 2 | 156 | PfizerINDUSTRY | 12 | Jun 23, 2021 | clinicaltrials |
| NCT02435680 | Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC)(TNBC) | completed | Phase 2 | 50 | Novartis PharmaceuticalsINDUSTRY | 12 | Jun 21, 2021 | clinicaltrials |
| NCT01211483 | Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 222 | Daiichi SankyoINDUSTRY | 13 | Jun 16, 2021 | clinicaltrials |
| NCT00967343 | Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor | terminated | Phase 2 / Phase 3 | 40 | Kiadis PharmaINDUSTRY | 7 | Jun 14, 2021 | clinicaltrials |
| NCT02574637 | Evaluation of Efficacy and Safety of Brazikumab (MEDI2070) in Participants With Active, Moderate to Severe Crohn's Disease | terminated | Phase 2 | 29 | AstraZenecaINDUSTRY | 12 | May 26, 2021 | clinicaltrials |
| NCT01220128 | Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer(INDUCT) | terminated | Phase 2 | 66 | GlaxoSmithKlineINDUSTRY | 7 | May 25, 2021 | clinicaltrials |
| NCT03411161 | S 81694 Plus Paclitaxel in Metastatic Breast Cancer | completed | Phase 1 / Phase 2 | 22 | Institut de Recherches Internationales ServierOTHER | 4 | May 25, 2021 | clinicaltrials |
| NCT01693562 | A Phase 1/2 Study to Evaluate MEDI4736 | completed | Phase 1 / Phase 2 | 1,022 | MedImmune LLCINDUSTRY | 9 | May 13, 2021 | clinicaltrials |
| NCT01271504 | E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Participants With Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 102 | Eisai Inc.INDUSTRY | 6 | May 12, 2021 | clinicaltrials |
| NCT03264066 | A Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Participants With Solid Tumors | completed | Phase 2 | 87 | Hoffmann-La RocheINDUSTRY | 6 | May 11, 2021 | clinicaltrials |
| NCT03466320 | DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2(DEPLETHINK) | completed | Phase 1 / Phase 2 | 21 | Celyad Oncology SAINDUSTRY | 2 | May 4, 2021 | clinicaltrials |
| NCT03754179 | Dabrafenib/Trametinib/Hydroxychloroquine for Advanced Pretreated BRAF V600 Mutant Melanoma(COMBI-R2) | unknown | Phase 1 / Phase 2 | 63 | Universitair Ziekenhuis BrusselOTHER | 1 | Apr 28, 2021 | clinicaltrials |
| NCT00896480 | Study of GSK2132231A Antigen-Specific Cancer Immunotherapeutic in Patients With Inoperable Metastatic Cutaneous Melanoma | completed | Phase 2 | 24 | GlaxoSmithKlineINDUSTRY | 2 | Apr 8, 2021 | clinicaltrials |
| NCT01251640 | Combination With Gemcitabine in Advanced Pancreatic Cancer(BAGPAC) | completed | Phase 1 / Phase 2 | 90 | BayerINDUSTRY | 9 | Apr 8, 2021 | clinicaltrials |
| NCT01610336 | A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment | completed | Phase 2 | 161 | Novartis PharmaceuticalsINDUSTRY | 14 | Apr 8, 2021 | clinicaltrials |
| NCT01915589 | Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC) | completed | Phase 2 | 16 | BayerINDUSTRY | 17 | Apr 8, 2021 | clinicaltrials |
| NCT01915602 | Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC) | completed | Phase 2 | 14 | BayerINDUSTRY | 21 | Apr 8, 2021 | clinicaltrials |
| NCT02552121 | Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 33 | Seagen Inc.INDUSTRY | 5 | Apr 8, 2021 | clinicaltrials |
| NCT02379845 | NBTXR3 Crystalline Nanoparticles and Radiation Therapy in Treating Randomized Patients in Two Arms With Soft Tissue Sarcoma of the Extremity and Trunk Wall | completed | Phase 2 / Phase 3 | 180 | NanobiotixINDUSTRY | 13 | Apr 6, 2021 | clinicaltrials |
| NCT01302496 | Autologous TriMix-DC Therapeutic Vaccine in Combination With Ipilimumab in Patients With Previously Treated Unresectable Stage III or IV Melanoma(TriMix-Ipi) | completed | Phase 2 | 39 | Bart NeynsOTHER | 1 | Mar 29, 2021 | clinicaltrials |
| NCT04495010 | Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants(CheckMate 7UA) | withdrawn | Phase 2 | 0 | Bristol-Myers SquibbINDUSTRY | 16 | Mar 19, 2021 | clinicaltrials |
| NCT02162719 | A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors(LOTUS) | completed | Phase 2 | 124 | Genentech, Inc.INDUSTRY | 8 | Mar 10, 2021 | clinicaltrials |
| NCT01783444 | A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer.(BOLERO-6) | completed | Phase 2 | 309 | Novartis PharmaceuticalsINDUSTRY | 18 | Feb 26, 2021 | clinicaltrials |
| NCT02414568 | Bendamustine Study in Classical Hodgkin Lymphoma Patients Over 60 Treated by Prednisone, Vinblastine and Doxorubicin(PVAB) | completed | Phase 2 | 90 | The Lymphoma Academic Research OrganisationOTHER | 2 | Feb 21, 2021 | clinicaltrials |
| NCT01927341 | Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors | completed | Phase 1 / Phase 2 | 53 | PfizerINDUSTRY | 7 | Feb 18, 2021 | clinicaltrials |
| NCT00005944 | Second-look Surgery With or Without Intraperitoneal Chemotherapy in Treating Patients With Recurrent Colorectal Cancer | terminated | Phase 2 | — | UNICANCEROTHER | 2 | Feb 17, 2021 | clinicaltrials |
| NCT01207440 | Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL)(PACE) | completed | Phase 2 | 449 | Ariad PharmaceuticalsINDUSTRY | 11 | Feb 2, 2021 | clinicaltrials |
| NCT02822157 | Circulating Tumor DNA Guiding (Olaparib) Lynparza® Treatment in Ovarian Cancer(CLIO) | unknown | Phase 2 | 160 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Jan 29, 2021 | clinicaltrials |
| NCT02470533 | Transarterial Chemoembolization Versus Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma(TRENDY) | terminated | Phase 2 | 100 | Erasmus Medical CenterOTHER | 3 | Jan 27, 2021 | clinicaltrials |
| NCT04170959 | The Addition of Metformin to Definitive Radiotherapy in Patients With Stage III NSCLC(RADFORMIN) | terminated | Phase 2 | 3 | ethisch.comite@uza.beOTHER | 1 | Jan 15, 2021 | clinicaltrials |
| NCT02910063 | Study to Evaluate Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory (R/R) Aggressive B-Cell NHL | completed | Phase 2 / Phase 3 | 41 | AmgenINDUSTRY | 8 | Jan 13, 2021 | clinicaltrials |
| NCT00760929 | A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC). | terminated | Phase 2 | 171 | Hoffmann-La RocheINDUSTRY | 11 | Jan 5, 2021 | clinicaltrials |
| NCT03742713 | Efficacy Study of CPC634 (CriPec® Docetaxel) in Platinum Resistant Ovarian Cancer(CINOVA) | completed | Phase 2 | 25 | Cristal TherapeuticsINDUSTRY | 3 | Dec 28, 2020 | clinicaltrials |
| NCT00885196 | A Dose Finding Study of AEB071 Assessing Psoriasis Area and Severity Index in Patients With Plaque Psoriasis | completed | Phase 2 | 336 | Novartis PharmaceuticalsINDUSTRY | 9 | Dec 22, 2020 | clinicaltrials |
| NCT02308020 | A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain | completed | Phase 2 | 162 | Eli Lilly and CompanyINDUSTRY | 9 | Dec 19, 2020 | clinicaltrials |
| NCT00411528 | Efficacy and Safety of Patupilone in Men (≥18 Years) With Metastatic Hormone Refractory Prostate Cancer | completed | Phase 2 | 185 | Novartis PharmaceuticalsINDUSTRY | 8 | Dec 17, 2020 | clinicaltrials |
| NCT00670592 | Study of HCD122 in Adults With Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prior Therapies | completed | Phase 1 / Phase 2 | 111 | Novartis PharmaceuticalsINDUSTRY | 11 | Dec 17, 2020 | clinicaltrials |
| NCT01402401 | Phase II of AUY922 in Second-line Gastric Cancer in Combination With Trastuzumab in HER2 Positive Patients | terminated | Phase 2 | 21 | Novartis PharmaceuticalsINDUSTRY | 8 | Dec 10, 2020 | clinicaltrials |
| NCT01562899 | A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors | terminated | Phase 1 / Phase 2 | 77 | PfizerINDUSTRY | 8 | Dec 10, 2020 | clinicaltrials |
| NCT03234465 | Efficacy, Safety and Tolerability of AG013 in Oral Mucositis Compared to Placebo When Administered Three Times Per Day | terminated | Phase 2 | 200 | Oragenics, Inc.INDUSTRY | 4 | Nov 23, 2020 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials